Boston Commerce Limited
Incorporated in 1995, Boston Bio Systems
Ltd is in the business of trading in goods
e.g. Medical equipment, testing kits,
instruments etc.[1]
- Market Cap ₹ 4.00 Cr.
- Current Price ₹ 5.71
- High / Low ₹ 11.0 / 5.13
- Stock P/E
- Book Value ₹ 7.60
- Dividend Yield 0.00 %
- ROCE 0.11 %
- ROE -10.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.75 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 2.14%
- Company has a low return on equity of -6.94% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.15 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.00 | 0.19 | 0.48 | |
| 0.27 | 0.16 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.14 | 0.74 | 0.47 | |
| Operating Profit | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | 0.01 |
| OPM % | -125.00% | -6.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -289.47% | 2.08% | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.59 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | -0.58 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||
| -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | -0.58 | |
| EPS in Rs | -0.21 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | -0.79 | -0.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 153% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -7% |
| Last Year: | -10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
| Reserves | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.41 | -0.41 | -0.55 | -1.10 | -1.68 |
| 0.14 | 0.12 | 0.12 | 0.12 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 5.44 | 0.96 | |
| 0.00 | -0.01 | -0.01 | -0.01 | 1.46 | 1.90 | 2.60 | 3.11 | 3.11 | 3.25 | 3.57 | 1.09 | |
| Total Liabilities | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 | |
| Total Assets | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
Cash Flows
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 0.00 | 0.00 | 0.97 | -0.03 | -0.02 | 0.13 | 0.00 | 0.00 | 0.00 | -4.59 | 5.12 | |
| 0.00 | 0.00 | 0.00 | -0.91 | 0.00 | 0.00 | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.58 | -5.08 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.06 | -0.03 | -0.02 | 0.05 | 0.00 | 0.00 | 0.00 | -0.01 | 0.04 |
| Free Cash Flow | 1.00 | 0.00 | 0.00 | 0.97 | -0.03 | -0.02 | 0.13 | 0.00 | 0.00 | 0.00 | -4.59 | 5.12 |
| CFO/OP | -667% | 0% | 0% | 835% | 51,200% |
Ratios
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | 1,308.79 | 5,532.63 | 0.00 | |||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 11.59 | |||||||
| Days Payable | 1,488.97 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | -168.60 | 5,532.63 | 0.00 | |||
| Working Capital Days | -425.83 | -292.00 | -876.00 | 4,745.00 | 226.30 | 661.13 | 453.64 | 10,585.00 | 836.46 | |||
| ROCE % | -2.05% | -0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.89% | -5.89% | 0.11% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Current Ratio ratio |
|
|||||||
| Debt-Equity Ratio ratio |
||||||||
| Inventory Value INR Lakhs |
||||||||
| Number of Employees count |
||||||||
Extracted by Screener AI
Documents
Announcements
- Revised Financial Results For Quarter And Year Ended 31St March, 2026 10 Jun
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th June, 2026 Pursuant To Regulation 30 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015 .
5 Jun - Board on 5 June 2026 approved initiating capital reduction and write-off scheme, subject to approvals.
-
Board Meeting Intimation for Prior Intimation For The Board Meeting To Be Held On 5Th June, 2026
1 Jun - Board meeting on June 5, 2026 to consider share capital reduction proposal.
-
Financial Results For The Quarter And Year Ended 31St March, 2026
30 May - Board approved audited standalone results for quarter and year ended 31 March 2026; auditors issued unmodified opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th May, 2026
30 May - Board approved audited standalone results for quarter and year ended 31 March 2026; auditors gave unmodified opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2000
from bse
-
Financial Year 1999
from bse
Business Overview:[1]
BBSL specializes in jobwork for herbal and health-related products for formulation companies. Company also has plans to enter the medical field which includes the sales and servicing of medical equipment